Biofrontera Inc (BFRI) FinancialsBFRIBiofrontera Inc

Evaluating the bottom line, Biofrontera Inc maintains a gross margin of 79.92%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4.37%, while the net margin is -5.03%. These profitability ratios, combined with a Return on Equity (ROE) of -988.35%, provide a clear picture of how effectively BFRI converts its operational activities into shareholder value.

In the context of the broader market, BFRI competes directly with industry leaders such as GNTA and CLRB. With a market capitalization of $23.62M, it holds a significant position in the sector. When comparing efficiency, BFRI's gross margin of 79.92% stands against GNTA's N/A and CLRB's N/A. Such benchmarking helps identify whether Biofrontera Inc is trading at a premium or discount relative to its financial performance.

Biofrontera has demonstrated significant revenue growth, with Q1 2026 product revenues of $10.1 million, a 17% increase from the previous year. The gross margin has also improved to approximately 80%, indicating effective cost control and operational efficiency. Despite these positives, the company has reported net losses in recent quarters, which may raise concerns for long-term investors.